Targets › PROS1
1 program from 1 company in 4 trials: 3 Phase 4, 1 Phase 3; Cardiovascular, Gastroenterology, Hematology; next expected readout Apr 2027.
Anticoagulant plasma protein which directly binds coagulation factors Va (F5) and Xa (F10) and inhibits their activity. Acts independently of activated protein C. Also acts as a ligand for tyrosine-protein kinase receptors AXL and TYRO3, whose signaling is implicated in cell growth and survival, cell adhesion and cell migration. (UniProt, P07225)
Open in Phaseline: the race on PROS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CSL Behring | Prothrombin Complex Concentrate (BE1116) Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein | F7, PROS1, PROC, F9, F2 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver Cirrhosis | Apr 2027 |
Complex Cardiovascular Surgery With Cardiopulmonary Bypass (1) Cardiac Valve Disease (1) Hemophilia (1) Liver Cirrhosis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.